Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Aclaris Therapeutics, Inc.

CIK: 1557746 Ticker: ACRS

Exhibit 99.1

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights

 

 

 

 

 

  

Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

 

 

Projected Cash Runway into the Third Quarter of 2021

 

 

  

Management to Host Conference Call at 5:00 PM ET today

 

 

Wayne, PA  – February 25, 2020 (GLOBE NEWSWIRE) – 

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year 2019 and provided research and development (R&D) and business highlights.

 

“In 2019, we repositioned the company to focus on our core competency in developing small molecule kinase inhibitors.  Thus far, we are very pleased with the progression of our immuno-inflammatory pipeline, as well as with the positive results from our Phase 1 clinical trial of ATI-450, an oral small molecule MK2 inhibitor,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. “We look forward to initiating a Phase 2a trial of ATI-450 in subjects with rheumatoid arthritis in the first half of this year and executing on our new business plan.”

 

R&D Highlights:  

·

ATI-450:  

o

ATI-450 is an investigational oral small molecule MK2 inhibitor.

o

ATI-450-PKPD-101:  A  Phase 1 single and multiple ascending dose  (SAD/MAD) trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered ATI-450 in 77 healthy subjects.

§

Preliminary  data from this trial demonstrated that ATI-450:

·

resulted in marked inhibition of TNFα, IL1β, IL8, and IL6;

·

was generally well-tolerated at all doses tested in the trial. The most common adverse events (reported by 2 or more subjects who received ATI-450) observed during the trial were dizziness, headache, upper respiratory tract infection, constipation, abdominal pain, and nausea;

·

had dose-proportional pharmacokinetics (PK) with a terminal half-life of 9-12 hours in the MAD cohort; and

·

had no meaningful food effect or drug-drug interaction with methotrexate.

o

ATI-450-RA-201:  Aclaris intends to initiate a Phase 2a clinical trial for ATI-450 in subjects with rheumatoid arthritis in the first half of 2020.  

o

Aclaris is also planning to initiate a Phase 2a clinical trial of ATI-450 for an additional immuno-inflammatory indication.

 

·

ATI-1777:

o

ATI-1777 is an investigational topical soft-Janus Kinase (JAK)  inhibitor compound that Aclaris is developing as a potential treatment for moderate-to-severe atopic dermatitis.

o

Aclaris expects to submit an IND for ATI-1777 for the treatment of atopic dermatitis in mid-2020.  

o

If the IND is allowed, Aclaris expects to initiate a Phase 1/2 clinical trial in both healthy subjects and subjects with atopic dermatitis in the second half of 2020 evaluating ATI-1777 as a potential topical treatment for moderate-to-severe atopic dermatitis.  

 

·

ATI-2138:

o

ATI-2138 is an investigational oral ITK/TXK/JAK3  (ITJ) inhibitor compound that Aclaris is developing as a potential treatment for psoriasis and/or inflammatory bowel disease.

o

Aclaris expects to submit an IND for ATI-2138 in the fourth quarter of 2020 or the first quarter of 2021.

 

Corporate Highlights:

·

Divested RHOFADE (oxymetazoline hydrochloride) cream, 1% to EPI Health, LLC and repaid in full $30 million term loan with Oxford Finance LLC, in October 2019.

·

Appointed Vincent Milano to the Board in January 2020.

 

Business Development Highlights:

·

Aclaris continues to pursue strategic alternatives, including seeking partners for:

 

o

A-101 45% Topical Solution: to obtain regulatory approval and commercialize A-101 45% Topical Solution, an investigational compound, as a potential treatment for common warts (verruca vulgaris);

o

ATI-501 & ATI-502: to further develop, obtain regulatory approval and commercialize ATI-501 (oral) and ATI-502 (topical), investigational JAK 1/3 inhibitor compounds, as potential treatments for alopecia; and

o

ESKATA:  to commercialize ESKATA® (hydrogen peroxide) topical solution, 40% (w/w).

 

Financial Highlights:

Liquidity and Capital Resources

As of December 31, 2019, Aclaris had aggregate cash, cash equivalents and marketable securities of $75.0 million compared to $168.0 million as of December 31, 2018. For the quarter and year ended December 31, 2019, net cash used in operating activities was $20.4 million and $96.4 million, respectively.  As of December 31, 2019, Aclaris had no long-term debt outstanding and had approximately 41.5 million shares of common stock outstanding. 

   

Aclaris anticipates that its cash, cash equivalents and marketable securities as of December 31, 2019, will be sufficient to fund its operations into the third quarter of 2021, without giving effect to any potential business development transactions or financing activities.

Fourth Quarter 2019 and Year-to-Date Financial Results

·

The accompanying consolidated statements of operations and selected consolidated balance sheet data have been recast for all periods presented to reflect the assets, liabilities, revenue and expenses related to Aclaris’ commercial products as discontinued operations. The accompanying financial statement data are generally presented in conformity with Aclaris’ historical format.  Aclaris believes this format provides comparability with its previously filed financial statements. 

·

Total costs and expenses from continuing operations for the fourth quarter of 2019 were $18.4 million, compared to $26.9 million for the fourth quarter of 2018. For the year ended December 31, 2019, total costs and expenses were $115.3 million, compared to $90.9 million in 2018.

 

o

These amounts included non-cash stock-based compensation expenses of $3.2 million and $16.1 million for the quarter and year ended December 31, 2019, respectively, compared to $4.2 million and $16.6 million for the prior year periods, respectively.

o

For the year ended December 31, 2019, there was also a $18.5 million non-cash charge for the impairment of goodwill. There was no such charge in the prior year.

·

R&D expenses were $11.5 million and $64.9 million for the quarter and year ended December 31, 2019, respectively, compared to $19.0 million and $60.8 million for the quarter and year ended December 31, 2018, respectively.

o

The year-over-year fourth quarter decrease of $7.5 million was mainly the result of Aclaris’ Phase 2 clinical trials of ATI-501 and ATI-502 and two pivotal Phase 3 clinical trials of A-101 45% Topical Solution, which were at or near completion in the third quarter of 2019, as well as a reduction in personnel-related costs.

o

These reductions were offset by increased expenses related to Aclaris’ preclinical development programs and the Phase 1 clinical trial for ATI-450 which was initiated in 2019, and by a milestone expense related to one of Aclaris’ licensing agreements.

·

General and administrative expenses were $5.8 million and $27.2 million for the quarter and year ended December 31, 2019, respectively, compared to $6.6 million and $25.6 million for the quarter and year ended December 31, 2018, respectively.

·

Loss from continuing operations was $19.2 million for the fourth quarter of 2019, compared to $24.7 million for the fourth quarter of 2018. Loss from continuing operations was $113.5 million for the year ended December 31, 2019, compared to $82.1 million for the year ended December 31, 2018.

·

The gain from discontinued operations was $0.6 million for the fourth quarter of 2019, compared to a loss of $13.9 million for the fourth quarter of 2018. The loss from discontinued operations was $47.8 million for the year ended December 31, 2019, compared to $50.6 million for the year ended December 31, 2018.

·

Net loss was $18.6 million for the fourth quarter of 2019, compared to net loss of $38.6 million for the fourth quarter of 2018, and was $161.4 million for the year ended December 31, 2019, compared to $132.7 million for the year ended December 31, 2018.

 

Company to Host Conference Call

Management will conduct a conference call at 5:00 PM ET today to discuss Aclaris’ financial results and provide a general business update.  The conference call will be webcast live over the Internet and can be accessed by logging on to the “Investors” page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the call.

To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 9958112 prior to the start of the call.

 

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.

 

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Aclaris’ drug candidates, including the availability of data from its clinical trials,  timing for initiation of clinical trials and timing for regulatory filings, its plan to pursue strategic alternatives for its drug candidates and for ESKATA,  and its belief that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations into the third quarter of 2021. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2019  and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "SEC filings” section of the Investors page of Aclaris' website at http://www.aclaristx.com. Any forward-

 

looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Aclaris Therapeutics, Inc.

Consolidated Statements of Operations

(unaudited, in thousands, except share and per share data)

 

 

Three Months Ended

 

Year Ended

 

 

December 31,

 

December 31,

 

    

2019

    

2018

    

2019

    

2018

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

 

$

 

$

 

$

Contract research

 

 

1,095

 

 

1,272

 

 

4,227

 

 

4,651

Other revenue

 

 

 

 

500

 

 

 

 

1,500

Total revenue, net

 

 

1,095

 

 

1,772

 

 

4,227

 

 

6,151

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (1)

 

 

1,028

 

 

1,266

 

 

4,055

 

 

4,329

Research and development (1)

 

 

11,540

 

 

19,022

 

 

64,899

 

 

60,841

Sales and marketing (1)

 

 

44

 

 

82

 

 

671

 

 

170

General and administrative (1)

 

 

5,765

 

 

6,561

 

 

27,156

 

 

25,591

Goodwill impairment

 

 

 

 

 

 

18,504

 

 

Amortization of definite-lived intangible

 

 

 

 

 

 

 

 

Total costs and expenses

 

 

18,377

 

 

26,931

 

 

115,285

 

 

90,931

Loss from operations

 

 

(17,282)

 

 

(25,159)

 

 

(111,058)

 

 

(84,780)

Other (expense) income, net

 

 

(1,895)

 

 

487

 

 

(2,484)

 

 

2,676

Loss from continuing operations

 

 

(19,177)

 

 

(24,672)

 

 

(113,542)

 

 

(82,104)

Gain / (loss) from discontinued operations (1)

 

 

583

 

 

(13,879)

 

 

(47,812)

 

 

(50,634)

Net loss

 

$

(18,594)

 

$

(38,551)

 

$

(161,354)

 

$

(132,738)

Net loss per share, basic and diluted

 

$

(0.45)

 

$

(0.99)

 

$

(3.90)

 

$

(4.03)

Weighted average common shares outstanding, basic and diluted

 

 

41,405,657

 

 

38,760,676

 

 

41,323,921

 

 

32,909,762

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Amounts include stock-based compensation expense as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

$

249

 

$

206

 

$

703

 

$

766

Research and development

 

 

358

 

 

1,564

 

 

5,091

 

 

6,480

Sales and marketing

 

 

 

 

 

 

 

 

General and administrative

 

 

2,581

 

 

2,381

 

 

10,288

 

 

9,317

Gain / (loss) from discontinued operations

 

 

(7)

 

 

805

 

 

95

 

 

3,492

Total stock-based compensation expense

 

$

3,181

 

$

4,956

 

$

16,177

 

$

20,055

 

 

Aclaris Therapeutics, Inc.

Selected Consolidated Balance Sheet Data

(unaudited, in thousands)

 

 

 

 

 

 

 

 

 

    

December 31, 2019

    

December 31, 2018

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and marketable securities

 

$

75,015

 

$

167,972

 

Total assets

 

 

98,297

 

 

275,566

 

Total current liabilities

 

 

22,432

 

 

27,342

 

Total liabilities

 

 

28,385

 

 

60,442

 

Total stockholders' equity

 

 

69,912

 

 

215,124

 

 

 

 

Aclaris Contact

Michael Tung, M.D.
Corporate Strategy / Investor Relations
484-329-2140
mtung@aclaristx.com

 

 

aclaris-final-logo-color.jpg

 


The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Tuesday, February 25, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Legal
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Income
Product
Shares
Cash Flow
Other
Inside Aclaris Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Operations And Comprehensive Loss (Parenthetical)
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
Accrued Expenses
Accrued Expenses (Details)
Accrued Expenses (Tables)
Agreements Related To Intellectual Property
Agreements Related To Intellectual Property (Details)
Debt
Debt (Details)
Discontinued Operations
Discontinued Operations (Details)
Discontinued Operations (Tables)
Discontinued Operations - Assets And Liabilities (Details)
Discontinued Operations - Cash Flow (Details)
Discontinued Operations - Loss (Details)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (Details)
Fair Value Of Financial Assets And Liabilities (Tables)
Fair Value Of Financial Assets And Liabilities - By Type (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Deferred Assets And Liabilities, Cfds (Details)
Income Taxes - Rate Reconciliation (Details)
Income Taxes - Tax Cuts And Jobs Act (Details)
Income Taxes - Valuation Allowance And Unrecognized Tax Benefits (Details)
Intangible Assets
Intangible Assets (Details)
Intangible Assets (Tables)
Intangible Assets - Future Amortization Expenses (Details)
Leases
Leases (Details)
Leases (Tables)
Leases - Finance Leases (Details)
Leases - Future Maturities Of Lease Liabilities (Details)
Leases - Lease Costs (Details)
Leases - Supplemental Information Related To Operating And Finance Leases (Details)
Legal Proceedings
Legal Proceedings (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Net Loss Per Share (Tables)
Net Loss Per Share - Anti-Dilution (Details)
Organization And Nature Of Business
Organization And Nature Of Business (Details)
Property And Equipment, Net
Property And Equipment, Net (Details)
Property And Equipment, Net (Tables)
Related Party Transactions
Related Party Transactions (Details)
Restructuring Charges
Restructuring Charges (Details)
Retirement Savings Plan
Retirement Savings Plan (Details)
Rhofade
Rhofade (Tables)
Rhofade - Amount Paid For Assets Acquired (Details)
Rhofade - Summary Of Fair Value Assets Acquired (Details)
Segment Information
Segment Information (Details)
Segment Information (Tables)
Stock-Based Awards
Stock-Based Awards (Details)
Stock-Based Awards (Tables)
Stock-Based Awards - Compensation (Details)
Stock-Based Awards - Option Activity (Details)
Stock-Based Awards - Rsus (Details)
Stockholders' Equity
Stockholders' Equity (Details)
Stockholders' Equity - Other Offerings (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Goodwill (Details)
Summary Of Significant Accounting Policies - Intangible Assets (Details)
Summary Of Significant Accounting Policies - Property And Equipment (Details)
Summary Of Significant Accounting Policies - Recent Pronouncements (Details)
Summary Of Significant Accounting Policies - Segments (Details)
Summary Of Significant Accounting Policies - Stock-Based Compensation (Details)
Ticker: ACRS
CIK: 1557746
Form Type: 10-K Annual Report
Accession Number: 0001558370-20-001325
Submitted to the SEC: Tue Feb 25 2020 4:32:03 PM EST
Accepted by the SEC: Tue Feb 25 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-20-001325.htm